SPRYARS Pharmaceuticals, Inc.
Price
-56%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
A flag to check, growth steady, the market against it.
Charts
As reported to the SEC, without any scoring.
ARS Pharmaceuticals, Inc. (SPRY) reported revenue of $34M in Q2 2026 (quarter ended Jun 30, 2026), up 114% from the same quarter a year earlier. That came with net loss of $62M. For the full year FY2025, revenue was $84M (−5.5% year on year) and net income −$171M. The next results filing is expected around Nov 9, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 13, 2026ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results.Earnings release · press release
- Jul 17, 2026On July 15, 2026, Richard Lowenthal resigned as a member of the Board of Directors (the “Board”) of ARS Pharmaceuticals, Inc. (the “Company”), effective immediately.Director or officer change · Form 8-K
- Jul 7, 2026On July 7, 2026, the Board of Directors (the “Board”) of ARS Pharmaceuticals, Inc. (the “Company”) appointed the Company’s current President Donn Casale as the Company’s Chief Executive Officer, effective immediately, replacing Richard Lowenthal in such capacity.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.